UNSPSC 51314304: Carbinoxamine/methscopolamine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314304 Carbinoxamine/methscopolamine/pseudoephedrine (Commodity) describes a specific pharmaceutical combination product, but recent state and local procurement activity under this code does not reflect purchases of this drug formulation. Instead, the three most recent opportunities posted to this code span naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which match the nominal scope of the carbinoxamine combination. The mismatch suggests either miscoding at the source or that this Commodity code functions as a catch-all for pharmaceutical and related health-supply procurement that state and local procurement offices have not yet disaggregated into more granular codes. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing consortia administering multi-state pharmaceutical contracts (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These jurisdictions are acquiring finished pharmaceutical products, drug deactivation systems, and pharmacy benefit program services rather than raw chemical compounds or active pharmaceutical ingredients.

Recent activity clusters in Texas and Minnesota through cooperative purchasing vehicles and Florida through direct county procurement. Seminole County issued an IFB on June 30, 2026 (due July 26, 2023, a date appearing anomalous in source materials) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries required and FEMA funding potential. The Texas HHS Commission posted an RFI on April 3, 2026 for vendor capabilities in implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, framing it as exploratory market research ahead of formal RFP issuance. The Minnesota Department of Administration's MMCAP issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with pricing weighted at 75 percent and mandatory distribution through three authorized wholesalers. The code shows limited recent activity aligned to its stated pharmaceutical composition and instead reflects broader health-supply and pharmacy procurement outside traditional drug-formulation categories.